Homology Medicines, Inc. (NASDAQ:FIXX – Get Rating) saw a significant growth in short interest during the month of April. As of April 30th, there was short interest totalling 2,860,000 shares, a growth of 23.8% from the April 15th total of 2,310,000 shares. Approximately 7.1% of the shares of the stock are short sold. Based on an average trading volume of 538,500 shares, the short-interest ratio is presently 5.3 days.
NASDAQ FIXX traded up $0.08 on Tuesday, reaching $1.52. The company had a trading volume of 25,351 shares, compared to its average volume of 418,820. The firm has a market capitalization of $87.23 million, a price-to-earnings ratio of -0.87 and a beta of -0.20. Homology Medicines has a 1-year low of $1.39 and a 1-year high of $8.90. The company’s fifty day moving average is $2.44 and its 200-day moving average is $3.60.
Homology Medicines (NASDAQ:FIXX – Get Rating) last announced its earnings results on Monday, May 16th. The company reported $1.59 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $2.10. Homology Medicines had a negative net margin of 281.90% and a negative return on equity of 48.27%. Research analysts anticipate that Homology Medicines will post -1.73 earnings per share for the current year.
A number of research analysts have recently issued reports on FIXX shares. HC Wainwright cut their target price on shares of Homology Medicines from $30.00 to $20.00 and set a “buy” rating for the company in a research note on Monday, February 28th. Oppenheimer cut shares of Homology Medicines from an “outperform” rating to a “market perform” rating in a research report on Tuesday, February 22nd. Royal Bank of Canada cut shares of Homology Medicines from an “outperform” rating to a “sector perform” rating and dropped their target price for the company from $30.00 to $4.00 in a research report on Tuesday, February 22nd. Chardan Capital dropped their target price on shares of Homology Medicines to $14.00 and set a “na” rating for the company in a research report on Tuesday. Finally, Bank of America dropped their target price on shares of Homology Medicines from $25.00 to $9.00 and set a “buy” rating for the company in a research report on Tuesday, February 22nd. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $12.60.
Homology Medicines Company Profile (Get Rating)
Homology Medicines, Inc, a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders.
- Get a free copy of the StockNews.com research report on Homology Medicines (FIXX)
- The Institutions Are Capping Gains In Take-Two Interactive
- Walmart’s “Everyday Low Prices” Gets Burned By Inflation
- VMWare Inc: Strong Revenues and Excellent Potential
- Beware The Rebound In Home Depot
- Time to Ride These 3 Mid Cap Momentum Plays
Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.